產(chǎn)品名稱：Pimecrolimus 產(chǎn)品貨號：LC P-6040 產(chǎn)品規(guī)格：100 MG Pimecrolimus, a rapamycin (sirolimus) derivative, is a cell-selective inhibitor of inflammatory cytokines developed for the treatment of inflammatory skin diseases, such as allergic contact dermatitis, atopic dermatitis, plaque-type psoriasis, and irritant contact dermatitis. It reduces the production of inflammatory cytokines in T cells and mast cells and inhibits the release of preformed inflammatory mediators from mast cells. Stuetz, A., et al. "Pimecrolimus (Elidel, SDZ ASM 981)--preclinical pharmacologic profile and skin selectivity." Semin. Cutan. Med. Surg. 20: 233-241 (2001). In 13 of 26 (50%) lesions of vitiligo, repigmentation was noted after a 6 month treatment of 1% pimecrolimus with a median percentage of repigmentation of 72.9% (interquartile range: 30.5-98.3%). Total affected body surface area and duration of vitiligo tended to be inversely correlated with the success rate of treatment. Boone, B., et al. "Topical pimecrolimus in the treatment of vitiligo." Eur. J. Dermatol. 17: 55-61 (2007). Pimecrolimus is active against mild to moderate atopic dermatitis in *****s and children aged ≥ 2 years. Pimecrolimus improved the signs and symptoms of atopic dermatitis and postponed time to a major flare. Hebert, A.A. "Review of pimecrolimus cream 1% for the treatment of mild to moderate atopic dermatitis." Clin. Ther. 28: 1972-1982 (2006). Pimecrolimus is the active ingredient in the drug sold under the trade name Elidel®. This drug is an immunomodulating agent used in the treatment of atopic dermatitis (eczema). It is currently available as a topical cream. NOTE: The pimecrolimus sold by LC Laboratories is NOT Elidel®, and is NOT for human use. Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO and ethanol, up to about 25 mg/mL. Disposal: A
滬公網(wǎng)安備 31011002002623號
